HUP0002101A3 - Fluoroether compositions, process for producing them and methods for inhibiting their degradation - Google Patents

Fluoroether compositions, process for producing them and methods for inhibiting their degradation

Info

Publication number
HUP0002101A3
HUP0002101A3 HU0002101A HUP0002101A HUP0002101A3 HU P0002101 A3 HUP0002101 A3 HU P0002101A3 HU 0002101 A HU0002101 A HU 0002101A HU P0002101 A HUP0002101 A HU P0002101A HU P0002101 A3 HUP0002101 A3 HU P0002101A3
Authority
HU
Hungary
Prior art keywords
inhibiting
degradation
producing
methods
fluoroether
Prior art date
Application number
HU0002101A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Central Glass Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25148366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0002101(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Central Glass Co Ltd filed Critical Central Glass Co Ltd
Publication of HUP0002101A2 publication Critical patent/HUP0002101A2/hu
Publication of HUP0002101A3 publication Critical patent/HUP0002101A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Catalysts (AREA)
  • Steroid Compounds (AREA)
HU0002101A 1997-01-27 1998-01-23 Fluoroether compositions, process for producing them and methods for inhibiting their degradation HUP0002101A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/789,679 US5990176A (en) 1997-01-27 1997-01-27 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
PCT/US1998/001376 WO1998032430A1 (en) 1997-01-27 1998-01-23 Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid

Publications (2)

Publication Number Publication Date
HUP0002101A2 HUP0002101A2 (hu) 2001-05-28
HUP0002101A3 true HUP0002101A3 (en) 2002-03-28

Family

ID=25148366

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002101A HUP0002101A3 (en) 1997-01-27 1998-01-23 Fluoroether compositions, process for producing them and methods for inhibiting their degradation

Country Status (27)

Country Link
US (6) US5990176A (https=)
EP (2) EP1114641B1 (https=)
JP (5) JP3183520B2 (https=)
KR (1) KR100368672B1 (https=)
CN (3) CN1899271A (https=)
AR (2) AR011090A1 (https=)
AT (2) ATE320798T1 (https=)
AU (1) AU726733B2 (https=)
BG (2) BG65414B1 (https=)
BR (1) BR9806996A (https=)
CA (2) CA2278133C (https=)
CO (1) CO4920220A1 (https=)
CZ (1) CZ297092B6 (https=)
DE (2) DE69833884T2 (https=)
DK (2) DK1114641T3 (https=)
ES (2) ES2170474T3 (https=)
GR (1) GR3036190T3 (https=)
HU (1) HUP0002101A3 (https=)
IL (1) IL130150A (https=)
NO (1) NO993606L (https=)
NZ (1) NZ335994A (https=)
PL (1) PL334477A1 (https=)
PT (2) PT967975E (https=)
SK (1) SK284243B6 (https=)
TR (1) TR199901579T2 (https=)
WO (1) WO1998032430A1 (https=)
ZA (1) ZA98418B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
US6162443A (en) * 1998-01-09 2000-12-19 Abbott Laboratories Container for an inhalation anesthetic
US6074668A (en) * 1998-01-09 2000-06-13 Abbott Laboratories Container for an inhalation anesthetic
US20030200963A1 (en) * 1998-01-09 2003-10-30 Flament-Garcia Mary Jane Container for an inhalation anesthetic
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
EP1018827B1 (en) 1999-01-08 2004-05-06 Sony International (Europe) GmbH Synchronisation structure for OFDM system
TW523409B (en) 2000-09-15 2003-03-11 Baxter Int Container for inhalation anesthetic
ATE365034T1 (de) * 2003-09-10 2007-07-15 Cristalia Prod Quimicos Farm Stabile pharmazeutische zusammensetzung einer fluorether-verbindung für die anästhesie, verfahren zur stabilisierung einer fluorether- verbindung, verwendung eines stabilisierungsmittels zum ausschluss des abbaus einer fluorether-verbindung
BR0303489A (pt) * 2003-09-10 2005-07-05 Cristalia Prod Quimicos Farm Composição farmacêutica estabilizada de composto flúor-éter e método para inibir a degradação de composto flúor-éter. uso de agente estabilizante para inibir a degradação de composto flúor éter
US20060258755A1 (en) * 2005-04-18 2006-11-16 Terrell Ross C Preparation of sevoflurane with negligible water content
WO2009049460A1 (en) * 2007-10-15 2009-04-23 Jiangsu Hengrui Medicine Co., Ltd. New packaging material for sevoflurane
PL2244737T3 (pl) * 2008-01-22 2020-05-18 The Board Of Regents Of The University Of Texas System Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu
US20090275785A1 (en) 2008-05-01 2009-11-05 Barry Jones Distillation Method For The Purification Of Sevoflurane And The Maintenance Of Certain Equipment That May Be Used In The Distillation Process
US8563115B2 (en) 2008-08-12 2013-10-22 Xerox Corporation Protective coatings for solid inkjet applications
US8092822B2 (en) * 2008-09-29 2012-01-10 Abbott Cardiovascular Systems Inc. Coatings including dexamethasone derivatives and analogs and olimus drugs
US8283643B2 (en) * 2008-11-24 2012-10-09 Cymer, Inc. Systems and methods for drive laser beam delivery in an EUV light source
US8191992B2 (en) * 2008-12-15 2012-06-05 Xerox Corporation Protective coatings for solid inkjet applications
US9278048B2 (en) * 2009-05-06 2016-03-08 Baxter International, Inc. Pharmaceutical product and method of use
US9102604B1 (en) 2010-02-15 2015-08-11 Baxter International Inc. Methods for cleaning distilling columns
CN105193774B (zh) * 2015-09-21 2018-01-16 山东新时代药业有限公司 一种七氟烷吸入剂
CN105106182B (zh) * 2015-09-21 2017-12-29 山东新时代药业有限公司 七氟烷吸入剂
CA2952552C (en) 2016-11-02 2018-05-15 Central Glass Company, Limited Method for washing sevoflurane storage container and method for storing sevoflurane

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2992276A (en) * 1959-05-20 1961-07-11 Du Pont Process for preparing polyfluoro alkyl compounds
US3527813A (en) * 1966-10-03 1970-09-08 Air Reduction 1,1,2 - trifluoro - 2 - chloroethyl difluoromethyl ether and its method of preparation
US3689571A (en) * 1970-07-31 1972-09-05 Baxter Laboratories Inc Fluorinated ether
GB1499818A (en) * 1974-12-06 1978-02-01 Ici Ltd Anaesthetic composition
US4469898A (en) * 1979-12-26 1984-09-04 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
US4250334A (en) * 1979-12-26 1981-02-10 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
JP2786108B2 (ja) * 1994-03-31 1998-08-13 セントラル硝子株式会社 フルオロメチル−１，１，１，３，３，３−ヘキサフルオロイソプロピルエーテルの精製方法
IT1270239B (it) * 1994-06-17 1997-04-29 Zambon Spa Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid

Also Published As

Publication number Publication date
EP0967975A1 (en) 2000-01-05
JP2005279283A (ja) 2005-10-13
CA2278133A1 (en) 1998-07-30
NO993606L (no) 1999-09-24
JP3664648B2 (ja) 2005-06-29
JP3183520B2 (ja) 2001-07-09
DE69833884T2 (de) 2006-08-24
US20040048932A1 (en) 2004-03-11
ES2256104T3 (es) 2006-07-16
CA2278133C (en) 2001-06-26
IL130150A (en) 2004-09-27
CN1152674C (zh) 2004-06-09
BG103656A (en) 2000-04-28
CN1899271A (zh) 2007-01-24
NO993606D0 (no) 1999-07-23
CO4920220A1 (es) 2000-05-29
NZ335994A (en) 2000-08-25
CZ256199A3 (cs) 1999-11-17
AU5930098A (en) 1998-08-18
EP1114641A2 (en) 2001-07-11
BG65414B1 (bg) 2008-07-31
ATE320798T1 (de) 2006-04-15
DE69833884D1 (de) 2006-05-11
JP2000510159A (ja) 2000-08-08
IL130150A0 (en) 2001-03-19
TR199901579T2 (xx) 1999-12-21
EP1114641A3 (en) 2003-05-28
JP2001187729A (ja) 2001-07-10
PT1114641E (pt) 2006-05-31
DE69800928D1 (de) 2001-07-19
AR011090A1 (es) 2000-08-02
CA2626424A1 (en) 1998-07-30
ES2170474T3 (es) 2002-08-01
US6444859B2 (en) 2002-09-03
US6677492B2 (en) 2004-01-13
US6288127B1 (en) 2001-09-11
PT967975E (pt) 2001-11-30
PL334477A1 (en) 2000-02-28
HK1074434A1 (en) 2005-11-11
CN1244797A (zh) 2000-02-16
DK0967975T3 (da) 2001-09-17
US20060148906A1 (en) 2006-07-06
JP2006137769A (ja) 2006-06-01
GR3036190T3 (en) 2001-10-31
CN1560003A (zh) 2005-01-05
JP2006143742A (ja) 2006-06-08
US20030130359A1 (en) 2003-07-10
US20020016373A1 (en) 2002-02-07
DE69800928T2 (de) 2001-11-22
KR100368672B1 (ko) 2003-01-24
DK1114641T3 (da) 2006-05-15
BG109751A (bg) 2008-06-30
HUP0002101A2 (hu) 2001-05-28
SK284243B6 (sk) 2004-12-01
BR9806996A (pt) 2000-03-14
WO1998032430A1 (en) 1998-07-30
SK86199A3 (en) 2000-06-12
CZ297092B6 (cs) 2006-09-13
ATE201987T1 (de) 2001-06-15
AU726733B2 (en) 2000-11-16
US5990176A (en) 1999-11-23
EP1114641B1 (en) 2006-03-22
ZA98418B (en) 1999-04-20
CN1321958C (zh) 2007-06-20
KR20000070482A (ko) 2000-11-25
AR057610A2 (es) 2007-12-05
EP0967975B1 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
HUP0002101A3 (en) Fluoroether compositions, process for producing them and methods for inhibiting their degradation
GB2354765B (en) Dispersion composition and method for producing the same
HUP9700344A2 (en) Substituted quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP9902850A3 (en) Quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP0003309A3 (en) Imidazolyl-cyclic acetals, process for producing them and pharmaceutical compositions containing the same
MXPA98006731A (es) Procedimiento para producir n-acetil-d-glucosamina.
GR3030407T3 (en) Naphthyl compounds, intermediates, compositions, and methods
HUP9900120A3 (en) Benzosulfone derivatives, process for producing them and pharmaceutical compositions containing them
HUP9802422A3 (en) Substituted isoquinoline-3-carboxamide derivatives, process for producing them and pharmaceutical compositions containing them
HUP0100221A3 (en) Sustained release compositions, process for producing the same and utilization thereof
HUP0002893A3 (en) Substituted quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP0102084A3 (en) Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP0103224A3 (en) Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
AU1296099A (en) Methods and compositions for treating dermatoses
HUP9900936A3 (en) Isocyanate compositions, method for using same, use thereof for producing coatings, and resulting coatings
HUP0002424A3 (en) Hydrazine derivatives, pharmaceutical compositions comprising them, and method for producing them
HUP9802653A3 (en) Substituted imidazolidine derivatives, process for producing them, and pharmaceutical compositions containing them
HUP9702507A3 (en) Substituted purine derivatives, process for producing them and compositions containing them
HUP9901739A3 (en) Aminoisoquinolines and aminothienopyridine derivatives, process for producing thereof and pharmaceutical compositions containing them
HUP0002921A3 (en) Cyanoguanidines as cell proliferation inhibitors, process for producing them and pharmaceutical compositions containing them
AU1278100A (en) 2-acylamino-2-deoxy-glucono-1,5-lactones, method for obtaining same, compositions comprising them and uses
ZA966836B (en) Detergent compositions and process for preparing them.
HUP0001522A3 (en) Benzoimidazole derivatives, process for producing them and pharmaceutical compositions containing them
HU9700566D0 (en) Amino-alkyl- and acyl-amino-alkyl-ethers, process for producing them and their use as bradiquinine-receptor-antagonists
HUP0103316A3 (en) 2-ureido-pyrimidone derivatives, method for producing them, pharmaceutical compositions containing them and their use

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees